A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

PHASE4TerminatedINTERVENTIONAL

Enrollment

743

Participants

Timeline

Start Date

September 17, 2008

Primary Completion Date

January 16, 2012

Study Completion Date

January 16, 2012

Conditions

Human Papillomavirus Infection Leading to Cervical Cancer

Interventions

BIOLOGICAL

Cervarix

Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.

Trial Locations (2)

GSK Investigational Site, Makati City

GSK Investigational Site, Ermita, Manila